We characterized GBM patients' tumor and systemic immune contexture with aim to reveal the mechanisms of immunological escape, their impact on patient outcome, and identify targets for immunotherapy. Increased CD3 + T-cell infiltration was associated with prolonged survival independent of age, MGMT promoter methylation and post-operative treatment that implies potential for immunotherapy for GBM. Several mechanisms of escape were identified: within the tumor microenvironment: induced CD8 + CD28 − Foxp3 + T regs that may tolerize antigen presenting cells, elevated CD73 and CD39 ectonucleotidases that suppress T-cell function, and at the systemic level: elevated IL-10 levels in serum, diminished helper T-cell counts, and upregulated inhibitory CTLA-4.
Introduction
Glioblastoma (GBM) is the most frequent and malignant brain tumor classified as grade IV by the World Health Organization (Louis et al., 2007) and accounts for 52% of all gliomas. The current treatment combines surgical debulking with chemotherapy and radiotherapy, however, the patients' survival remains very low , emphasizing the need for continued search for novel and effective therapies. Identifying molecular markers that associate with beneficial patient survival is critical for highlighting important biological processes involved in disease progression and may guide the search for innovative therapies.
For a long time the brain was considered an immune privileged organ due to the presence of the blood brain barrier (BBB), lack of lymphatic drainage and of professional antigen presenting cells (APCs).
Therefore, brain tumors were considered protected from immune surveillance. However, recent investigations showed that activated immune cells can cross the BBB (Becher et al., 2000; Sehgal and Berger, 2000; Alter et al., 2003; Prendergast and Anderton, 2009) , which is also often disrupted at the tumor site, and that microglia can act as resident APCs (Becher et al., 2000; Yang et al., 2010a) . Thus, the role of the immune system in brain cancer has become a subject of intensive study. It has been shown, that the immune cells perform anti-tumor surveillance and display potential for killing the tumor cells (Costello et al., 2002; Tang et al., 2005; Carpentier and Meng, 2006; Ueda et al., 2007) . However, GBM develops multiple escape mechanisms, such as expression of inhibitory molecules (Rouas-Freiss et al., 2005; Gomez and Kruse, 2006; Malmberg and Ljunggren, 2006; Zhang, 2010) and release of soluble immunosuppressive factors (Zou et al., 1999; Gomez and Kruse, 2006; Malmberg and Ljunggren, 2006) . Moreover, the role of the immune system in cancer is ambiguous, as there exist immune cell subpopulations that promote tumor progression (de Visser et al., 2006; Fecci et al., 2006; Wang, 2008; Ostrand-Rosenberg and Sinha, 2009) and that are thought to be induced by the tumor cells. There is no consensus on the impact of tumor immune infiltration on the patient's overall outcome, nor are the mechanisms involved in the patients' systemic response to the tumor delineated.
In the present study we characterized the immune profile of GBM patients and identified several coordinated mechanisms of tumordriven immune suppression. A substantial number of functional studies describing tumor-immune interactions focused only on particular subpopulations and markers. The aim of our work was to broadly investigate the immune contexture of GBM patients both within the tumor microenvironment and at the systemic level. We highlight the coordinated anti-tumor immune responses and tumor-mediated immune escape mechanisms. Our results demonstrated a significant positive correlation of increased CD3 + and CD8 + cellular infiltration into the tumor with improved patient survival. The major mechanisms of tumor immune escape in GBM patients were (1) induction of CD8 + CD28 − Foxp3 + T regs , that could mediate the tolerization of
APCs by upregulating immunoglobulin-like transcript (ILT) inhibitory receptors and downregulating CD80, CD86 and CD40 costimulatory molecules (Fecci et al., 2006) and high surface expression of CD73 that could lead to T-cell suppression (Jeffes et al., 1993; Purdy and Campbell, 2009; Hausler et al., 2011) . Comparison between the GBM patients' and healthy donors' PBMCs and plasma also revealed systemic immunosuppression. Thus, detailed characterization of the patients' immune status is required for design of appropriate immunotherapy for GBM.
Materials and methods

Blood and tumor material
Patients' blood and GBM biopsies were obtained during surgical resections performed at the Haukeland University Hospital, Norway, between 2009 and 2011. The patients gave their written informed consent and the study was approved by the Norwegian regional Helse-Vest ethical board. Parts of the tumor were formalin fixed and paraffin embedded (FFPE). H&E-stained sections were prepared to define representative tumor regions and the neuropathologists at the department of pathology, Gades Institute, Haukeland University Hospital routinely confirmed GBM diagnosis according to the World Health Organization (WHO) classification (Louis et al., 2007) . Furthermore, patients diagnosed with GBM had routine follow-up with MRI interpreted by neuroradiologists at the department of radiology, Haukeland University Hospital, as part of their routine management. Eligibility criteria included availability of follow-up data, less than 50% necrosis in the sample, and only biopsies obtained at primary diagnosis were included. Clinical information was obtained by reviewing the medical records, and death certificates/registers. Patients were followed-up from the date of operation until death or December 2012. The median follow-up of the seven patients that were alive was 30 months, range 23-39 months. All patients were treated by surgery, radiotherapy and/or chemotherapy and survival determined as the time elapsed from the date of surgery to the date of death.
Part of the fresh tissue was dissociated by use of Neural Tissue Dissociation Kit as recommended by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). Cell suspension was frozen in 10% DMSO (Sigma, St. Louis, MO) and 10% fetal bovine serum (FBS) (PAA, Pasching, Austria) solution according to standard protocol. Peripheral blood was collected using BD Vacutainer® CPT™ Cell Preparation Tube with Sodium Citrate (BD Biosciences, Franklin Lakes, NJ) and Peripheral Blood Mononuclear Cells (PBMCs) were isolated and frozen as above. Patients' plasma was stored at −20°C., PBMCs and plasma were isolated from age and gender matched healthy donors (Table S1 ) using the same method.
Immunohistochemistry
FFPE tissue was subjected to immunohistochemistry using the avidinbiotin-peroxidase complex method according to the manufacturer's protocol (Vectastain, Vector laboratories, Burlingame, CA). FFPE sections from 65 patients were immunolabeled with rabbit anti-human CD3 (Dako, Glostrup, Denmark), mouse anti-human CD4 (Novocastra™ Leica Microsystems GmbH, Wetzlar, Germany) and mouse anti-human CD8α (Dako) primary antibodies according to standard protocols. Human tonsil tissue was used for positive control and staining with irrelevant primary antibody (MOC-31, Santa Cruz Biotechnology, Santa Cruz, CA) as negative control. CD3 + cells were quantified by morphometry and the result presented as percentage of total number of cells. Area fractions (%) of CD4 + and CD8 + cells were quantified on 89,400 μm 2 field of view (magnification 400×), minimum of 4 fragments, representing hot spots, per each section and were analyzed, using NIS-Elements BR v4 software (Nikon).
Bisulfite treatment and MGMT methylation analysis
For the analysis of MGMT promoter methylation, DNA was extracted from snap-frozen tumor tissue using the QIAamp DNEasy mini kit (Qiagen, Hilden, Germany). Bisulfite conversion was conducted as previously described (Mikeska et al., 2007) . (Fig. 3H) .
2.4.3. Gating strategy applied to GBM biopsy phenotyping Dead cells were excluded from the analysis based on Live/Dead staining (Fig. S1C ). We used Hoechst or TO-PRO®-3 iodide staining on fixed and permeabilized cells in addition to FSC and SSC parameters to include in our analysis only nucleated cells (Fig. S1B ). Doublets were excluded based on SSC-A vs. SSC-H plot. Tumor infiltrating-immune cells were defined as CD45 + cells (Fig. S1C ). Table 4 and Human TGF-β1 Single Plex Flex Set (BD Biosciences). Data were acquired on BD Canto and BD LSRFortessa flow cytometers and analyzed with FCAP Array Software (Soft Flow Inc., Pecs, Hungary).
Statistics
Patient survival was estimated using the Kaplan-Meier method (Kaplan and M.P., 1958) and compared between groups with the log rank test (Mantel, 1966) . Univariate analyses were performed to identify variables with significant prognostic impact (p b 0.05) and, these variables were further included in the Cox proportional hazards model. Backward stepwise selection was applied to select variables to adjust for effects of potential confounding variables including age (0-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80 years) and post-operative treatment, CD3 (grouped 0-10, 10-20, 20-30, 30-40) , CD8 and CD4 (grouped 0-1, 1-2, 2-3) gender and MGMT as categorical variables. To compare the patient and healthy donor group the non-parametric Wilcoxon signed rank test was used. When comparing more than two cell populations within patient GBM or between patients and donors we used One-Way ANOVA tests (Friedman and Kruskal-Wallis, respectively). In all analyses probability values less or equal to 0.05 were considered significant. Descriptive statistics are reported as mean, mean ± standard error of the mean (SEM). All statistical analyses were performed with the (SPSS) v11.0 software.
Results
Increased tumor infiltration of CD3
+ and CD8 + cells correlates with prolonged patient survival
Analysis of CD3, CD4 and CD8 expressing cells in 65 GBM biopsies revealed a great heterogeneity in the amounts and their spatial localization, both between and within the patients' tumors (Fig. 1A) . In some cases the immune cells were localized in hotspots in the vicinity of blood vessels and/or infiltrated the entire tumor ( immune cells in the 65 unassigned GBM biopsies and correlated the expression with the patients' outcome. The mean and the median survival of the patient population were 19.6 ± 1.8 and 11.7 ± 0.8 months respectively ( Fig. 2A ). Mean and median survival of females were 13.8 ± 2 and 9.5 ± 1.8 months respectively, compared to males 16.4 ± 1.9 and 9.8 ± 1.4 months respectively, (Table 2) . In univariate analyses, gender had no significant impact on patients' survival, Log Rank (Mantel-Cox) Chi-square 0.77, df = 1, p = 0.37. Although methylation of the methyl guanine DNA methyltransferase (MGMT) gene promoter is established as predictive of response to temozolomide chemotherapy (Hegi et al., 2005; Stupp et al., 2009 ), reports of its prognostic role have been variable (Costa et al., 2010) . In our material, MGMT promoter methylation was not significantly associated with patient survival, Log Rank (Mantel-Cox) Chi-square 2.82, df = 1, p = 0.093 ( Fig. 2B and Table 2 ). Preoperative treatment with steroids had no effect on outcome, Log Rank, Chi-square 5.196, df = 4, p = 0.268 (Table 2 ). Age at diagnosis was a significant prognostic factor, Log Rank (Mantel-Cox) Chi-square 14.11 df = 6, p = 0.028. Post-operative treatment had a significant effect on overall survival, p = 0.0001, ( 1D and Table S2 ).
Patients' T cells present a suppressed phenotype within the tumor microenvironment and a moderate immunosuppression was observed at the systemic level
To identify the phenotype of the tumor infiltrating immune cells impacting patients' outcome, 8 patients' biopsies randomly selected from the original cohort were dissociated and single cells analyzed using multicolor flow cytometry. We compared proportion and phenotype of tumor infiltrating T-cell subpopulations with paired patients' peripheral T-cells and with 9 gender and age matched healthy donors' T-cells. First, we observed that the proportion of T h in patients' blood was significantly diminished compared to normal donor (45.28% ± 7.20 and 65.68% ±2.10 of CD3 + cells, respectively, p = 0.0005, Fig. 3B and Table 3 ) and there was a tendency for further diminution within the tumor microenvironment (29.43% ±7.20 of CD3 + cells, Fig. 3B and Table 3 ). However, no significant differences in the percentage of CTL cells were found when we compared the blood of patients to donors and GBM biopsy ( Fig. 3A and Table 3 ). No significant difference was observed in the expression of the co-stimulatory receptor CD28 (Fig. 3C , D and Table 3 ) and L-selectin CD62L (Fig. 3E , Table 3 ) in patients' and donors' peripheral T h cells and CTLs, while it was down regulated in tumor infiltrating T h cells and CTLs when compared to patients' peripheral T cells (Fig. 3C , D, E and Table 3 ). Moreover, tumor infiltrating CTLs displayed decreased expression of the adhesion molecule CD56 when compared to patients' peripheral CTLs, while no difference was observed comparing patients' vs. donors' peripheral CTLs (Fig. 3F, Table 3 ). Significantly more of patients' peripheral T h cells compared to donors' expressed the inhibitory receptor CTLA-4, however, there was a trend for diminution within the tumor infiltrating T h (Fig. 3G, Table 3 ). Furthermore, we investigated the presence of T regs in 9 donors' and patients' peripheral blood and in 5 paired GBM biopsies. The naturally-occurring CD4 + CD25 high Foxp3 + T regs were not detected among the tumor infiltrating immune cells in our GBM patients (data not shown) and no difference was found in the proportions of these T regs within patients' vs. donors' peripheral T cells ( Fig. 3I and Table 3 ). However, in 60% (3/5) of the patients, CD8
+ CD28 − Foxp3 + T regs were identified and represented 2.08% ±0.99 of all T-cells (Fig. 3J ). They were not detected in the blood of both patients and controls. In addition, we examined the GBM biopsies for the presence of NK and B cells. They were not very abundant and represented 2.11% ±0.54 and 0.66% ±0.27 (n = 8) of all tumor infiltrating immune cells, respectively. Within all patients, NK cells were predominantly CD56 dim CD16 negative (Fig. 3K) and 57.45% ±12.05 expressed the activating receptor NKG2D (Fig. 3K) . Six patients' biopsies were analyzed for the presence of type I natural killer T-cells. However, they constituted only 1.13% ±0.65 of all T-cells (data not shown).
Tumor infiltrating macrophages/microglia present immunotolerized phenotypes
The tumor-induced population of CD8 + CD28 − Foxp3 + T regs detected in our patients' biopsies has been reported to mediate immune tolerization by up regulating the expression of inhibitory receptors: immunoglobulin-like transcripts 2, 3, and 4 (ILT2, -3, -4) and down regulating the expression of co-stimulatory molecules CD40, CD80 and CD86 on APCs (Wang, 2008) . Therefore, we investigated the phenotype of tumor infiltrating APCs (mainly macrophages/microglia). Remarkably, these cells represented the major subtype of immune cells in the tumor microenvironment, constituting 53.50% ±4.30 (n = 8) of all immune cells (Suppl Fig. 1 shows gating strategy). 13.21% ±6.90 of APCs expressed CD4 and 21.49% ±4.16 expressed CD8 (n = 8, Fig. 4A and B). Substantial proportions of APCs were positive for ILT2, ILT3 and ILT4 (38.60% ±6.79; 43.25% ±6.35 and 28.79% ±4.66, respectively, n = 8, Fig. 4A and C) . Moreover, these cells highly expressed HLA-G and HLA-E (40.34% ±5.93 and 61.11% ±4.72 of positive cells, respectively, n = 8, Fig. 4A and D) that are ligands for ILTs and NKG2A inhibitory receptor. Only small proportions of APCs expressed CD40, CD80 and CD86 (12.61% ±3.37, 4.14% ±2.38 and 15.73% ±4.12, respectively, n = 8, Fig. 4E and F) . On the other hand, we detected a proportion of APCs expressing MHC class I -related chains A and B (MICA and MICB) -ligands for the NKG2D activating receptor (26.53% ±6.60 and 8.39% ±2.71 of all APCs, n = 8, respectively, Fig. 4E and G). Interestingly, nearly half of APCs (46.58% ±9.54, n = 8, Fig. 4E and H) expressed NKG2D.
Tumor infiltrating immune cells display impaired expression of co-stimulatory molecules
Additionally, we investigated the tumor infiltrating immune cells for expression of co-stimulatory ligands and receptors important for immune function. Immune response can be stimulated upon binding of CD40 expressed on APCs to its ligand CD154 expressed on activated Tcells and some NK cells (Foy et al., 1996; Jyothi and Khar, 2000) . Our results show that in GBM biopsies 12.61% ±3.37 of APCs are CD40 + and all T-cells are CD154 − (n = 8, Fig. 5A ). We investigated the expression of CD27 and its ligand CD70 that are also involved in immune modulation (Garcia et al., 2004) . In our patient cohort, 33.49% ±4.00 of T-cells expressed CD70 whereas all T-cells were CD27 − (n = 8, all T-cells, n = 8, data not shown). However, the majority of CTLs (82.75% ± 3.30, n = 8, Fig. 5C ) expressed NKG2D.
Tumor integrated mechanisms of immune escape vs. potential immunogenicity
We analyzed the tumor cells for the expression of molecules potentially involved in immune escape or immunogenicity. Our results show that in all patients analyzed, the majority of tumor cells are positive for HLA-A,B,C (93.26% ±1.85, n = 8, Fig. 6A and B) . On the other hand, only small proportions of tumor cells expressed HLA-G and HLA-E (0.538% ±0.27 and 6.23% ±3.50, respectively, n = 8, Fig. 6A and B) . The tumor cells failed to express MICB and CD70 -ligands for activating receptors present on immune cells. However, a proportion of tumor cells were MICA positive (24.53% ±8.78, n = 8, Fig. 6A and C) . We also analyzed tumor cells for the expression of Fas and FasL. All tumor cells were negative for FasL while 21.54% ±4.37 expressed Fas (n = 8, Fig. 6A and D) . Additionally, we examined both tumor and tumor infiltrating immune cells for the expression of CD39 and CD73 ectonucleotidases that have been described to mediate immunosuppression of T cells (Hausler et al., 2011) . In our patients, larger proportions of tumor cells were positive for CD73 compared to APCs and T-cells (33.49% ±5.31 vs. 8.150% ±2.83 and 3.54 ± 0.90, respectively, n = 8, p N 0.05 and p = 0.0099, respectively, Fig. 6E ). Contrasting results were obtained for the CD39 molecule, which was highly expressed on APCs but not on tumor cells (84.61% ±2.74 vs. 6.48% ±1.98, p = 0.0003, n = 8, Fig. 6F ). We also detected CD39 + T-cells (15.29% ±4.05, n = 8, Fig. 6F ).
The tumor-immune cell interactions in the tumor microenvironment are summarized schematically in Fig. 6G .
The cytokine balance in patients' plasma is anti-inflammatory compared to healthy donors
We examined the concentration of 16 proteins in the patients' and donors' plasma. The concentration of IL-10 was significantly higher in patients' plasma and there was a trend for decreased concentration of IL-2 and IL-12 (Table 4 ). The concentrations of IL-5, MCP-1 and FasL were significantly lower compared to the healthy donors (Table 4) . There was no significant difference in the concentration of other proteins examined (Table 4) . Unexpectedly, the mean levels of VEGF in patients and donors were similar, contrary to other studies reporting significant increase of VEGF concentration in the plasma of brain tumor patients (Sciacca et al., 2004) . In most cases of both patients and donors, TGFβ plasma levels were undetectable (data not shown).
Discussion
The aim of our work was to perform an integrated characterization of GBM patients' immune contexture both within the tumor microenvironment and at the systemic level. All research reports referring to glioma immunity published so far present investigations focused on particular subpopulations and markers. However, simultaneous analysis of the multitude of immune defects in patients may help in designing novel immunotherapies, more individualized treatments and preempting possible escape mechanisms.
Contradictory reports exist (Dunn et al., 2007) regarding the prognostic value of immune infiltrates in GBM patients. Several recent studies observed positive correlation of increased numbers of glioma infiltrating lymphocytes with better patients' survival (Yang et al., 2010b; Lohr et al., 2011; Kim et al., 2012) , while some older reports describe negative (Safdari et al., 1985) or no correlation (Rossi et al., 1989) . These discordances could be related to different approaches used to identify lymphocyte subpopulations. In our study, increased infiltration of CD3 + immune cells in the tumor microenvironment was significantly associated with patients' improved survival, independent of age at diagnosis, MGMT promoter hypermethylation and postoperative treatment. Increased CD8 + immune cell infiltration was also significantly associated with improved survival independent of age at diagnosis but not postoperative treatment, while the level of CD4 + cell infiltrates did not significantly correlate with patient survival. CD3 + and CD8 + cells were prognostic for a very small number of patients and may be argued to lack clinical relevance, however, the association of CD3 + cells with almost double increased lifespan may underlie a very important fundamental function of these immune cells in tumor progression. MGMT promoter methylation was not correlated with patient survival and this can be explained by the relatively small sample size and the fact that we analyzed samples from only one clinical centre. Moreover, the prognostic value of MGMT promoter methylation has been questioned (Costa et al., 2010) . Future work will be required to validate these findings with larger patient cohorts obtained from multicenter clinics. The expression of CD4 and CD8 markers is not restricted to T lymphocytes, but has been also described on monocytes, macrophages and dendritic cells (Gibbings and Befus, 2009 ). Accordingly, APCs in our patient cohort did express CD4 and CD8. However, since CD3, CD4 and CD8 were strongly correlated, prognostic significance of CD8 + immune cell infiltration is related rather to the CTL subpopulation. However, since GBM still remains the tumor with the worst prognosis, we hypothesized that the inefficient immune surveillance and response occur due to partially impaired functionality of immune cells recruited to the tumor and/or systemic immunosuppression. The limitation of our study is the lack of functional experiments. However, most aberrations in immune cells functionality are closely related to their phenotype. Therefore, our study is highly relevant for translational research, as it resolves GBM patients' immune status. We observed that smaller proportions of tumor infiltrating T-cells expressed costimulatory receptor CD28 and CD56 -an adhesion molecule associated with increased cytotoxicity (Pittet et al., 2000 ) -compared to those from patients' peripheral blood. This suggests a decreased cytotoxic potential and co-stimulation of tumor infiltrating T-cells. On the other hand, T-cells infiltrating the tumor display a CD62L negative effector phenotype (Yang et al., 2011) . The majority of tumor infiltrating CTLs express also the NKG2D activating receptor (Bauer et al., 1999) . We observed a decreased proportion of T h cells within patients' peripheral T-cells. Those cells also expressed higher levels of the inhibitory receptor CTLA-4; however, it tends to decrease within the tumor microenvironment. On the other hand, an increased proportion of patients' T-cells expressed CD56. Therefore, we speculate that T-cells entering the brain are competent, however, once in the tumor microenvironment, they become suppressed and acquire immunotolerant features. Furthermore, we observed down-regulation of co-stimulatory pathways that play critical roles in immunity. Low expression of CD80 and CD86 on APCs and down-regulation of their receptor CD28 on T-cells impairs adaptive immune responses (Smith-Garvin et al., 2009; Ribot et al., 2012 ). Another co-stimulatory pathway affected in our GBM patients is the absent interaction of CD40 on APCs with its ligand CD154, normally expressed on activated T-cells (Foy et al., 1996; Jyothi and Khar, 2000) , but absent in TILs in our GBM patients.
Recently, increasing numbers of reports describe higher proportion and the immunosuppressive action of various T regs subpopulations in the peripheral blood and tumor microenvironment of cancer patients including glioma (Fecci et al., 2006; Heimberger et al., 2008; Sonabend et al., 2008; Wang, 2008; Jacobs et al., 2010) . Our results are in contrast with other studies demonstrating an increased proportion of CD4 + CD25 high Foxp3 + cells in the peripheral blood and tumor microenvironment of GBM patients (Fecci et al., 2006) . This might be explained by the small number of patients we examined, as in the previous reports the increased T regs fraction was not observed for all the patients (Fecci et al., 2006 population has been described to be induced by tumor and to mediate the tolerization of DCs and non-professional APCs by upregulating the expression of inhibitory receptors belonging to the ILT family and down-regulating co-stimulatory molecules CD40, CD80 and CD86 (Wang, 2008; Chui and Li, 2009) . Within the tumor infiltrating APCs we observed high expression of ILT2, ILT3 and ILT4 and decreased expression of CD40, CD80 and CD86, thus, we speculate that a CD8 + CD28 − Foxp3 + T regs -mediated immunotolerization occurs in GBM patients. This tumor immune escape mechanism has been reported in other cancers (Cortesini, 2007; Filaci et al., 2007) however it needs further investigation in the context of GBM. Moreover, high proportions of APCs were positive for HLA-E and HLA-G that are ligands for ILT2 and ILT4 (Shiroishi et al., 2003) . Furthermore, we show that APCs may support tumor-driven immunosuppression via surface expression of CD39 in addition to CD73 expressed on tumor cells. Ectonucleotidases CD39 and CD73 catalyze two-step degradation of extracellular ATP and ADP. Overexpression of those enzymes has been reported in cancer (Zhang, 2010) and leads to elevated level of extracellular adenosine and T-cell and NK cell suppression (Hausler et al., 2011) . Interestingly, the compartmentalization of CD39 and CD73 expression in our GBM patients suggests, that tumor cells adapt to the immune status within tumor microenvironment. On the other hand, a proportion of tumor infiltrating APCs expressed MICA, potentially providing stimulating signal for NK cells through the NKG2D receptor (Kloss et al., 2008; Eissmann et al., 2010) . Interestingly, APCs also expressed NKG2D receptor. This has not been reported in human APCs so far, while in rodents it is believed that NKG2D expression on activated macrophages plays an important role in immunity (Diefenbach et al., 2000) . We examined GBM cells for the presence of several surface molecules that are known to activate or inhibit immune cells. Tumor cells are described to be deficient in MHC class I expression and due to that they present potent target for NK cell mediated lysis via "missing self" mechanism (Purdy and Campbell, 2009) . To avoid that, they express non-classical MHC class I molecules HLA-E and HLA-G that bind inhibitory receptors on NK cell's surface (Mittelbronn et al., 2007) . However, in all patients we analyzed, the majority of tumor cells were positive for HLA-A,B,C that protects them from NK cell-mediated cytotoxicity by binding inhibitory receptors on NK cells (Purdy and Campbell, 2009 ). On the other hand, tumor cells were negative for HLA-G and HLA-E. NK cells represented 2.11% of all tumor infiltrating immune cells and had CD56 dim CD16
negative phenotype that was previously reported to represent greater activation in some tumors (Levy et al., 2011) . Furthermore upon incubation with tumor target cells, NK cells have been demonstrated to down-regulate CD16 (Grzywacz et al., 2007) . We also examined GBM cells for the expression of MICA and MICB -ligands for the activating receptor NKG2D expressed on NK cells and on a subset of CD8 T-cells. All tumor cells were MICB negative, however, some of them expressed MICA, potentially providing stimulating signals to CTLs and NK cells. In addition we found a proportion of tumor cells expressing Fas, thus representing potent target for Fasmediated apoptosis. Tumor cells did not display FasL surface expression, which has been described to induce apoptosis of tumor infiltrating immune cells (Gomez and Kruse, 2006) . These results suggest that GBM is resistant to autologous NK cell-mediated cytotoxicity due to MHC class I expression on the tumor cells. However, HLA-A,B,C expression makes the tumor potentially sensitive to CTL-mediated immune response and our finding of the positive correlation of increased CD3 + and CD8 + infiltration into the tumor with improved patients' survival supports this conclusion. Moreover, due to expression of MICA and absence of HLA-G and HLA-E surface expression, a proportion of tumor cells may be sensitive to allogeneic NK cell with KIR receptor-HLA ligand mismatch. In addition, our results reveal that the cytokine balance in GBM patients is shifted towards anti-inflammatory profile. IL-10 is an immunosuppressive cytokine, whereas Th1 cytokines induce T-cell maturation into T h1 type cells that perform cytotoxic functions and are potentially capable of defending against cancer (Kidd, 2003) . It has been described that the cytokine signaling in the periphery and in the brain influences each other (Quan and Herkenham, 2002) . In this context, there may be a link between elevated IL-10 in patients' plasma and overexpression of ILT receptors on tumor infiltrating immune cells, as such a correlation has already been suggested (Chui and Li, 2009 ).
In conclusion, our study showed beneficial role of immune cell infiltration into the tumor in GBM patients, despite multiple mechanisms of tumor immune escape. Our detailed investigation identified potent targets for enhancing immune response and/or overriding tumor-driven immunosuppression. An example of such a target is the inhibitory receptor CTLA-4. Ipilimumab, the anti-CTLA-4 antibody, has already been successfully applied in melanoma patients (Hodi et al., 2010; Robert et al., 2011) and in-vivo studies showed promising results in brain tumor (Fecci et al., 2007) . In GBM patients we observed upregulated expression of CTLA-4 in peripheral T h cells, thus we hypothesize that the therapy targeting this receptor may be also applicable in GBM as an adjuvant treatment.
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